1. Home
  2. NBXG vs EVO Comparison

NBXG vs EVO Comparison

Compare NBXG & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuberger Berman Next Generation Connectivity Fund Inc.

NBXG

Neuberger Berman Next Generation Connectivity Fund Inc.

HOLD

Current Price

$15.42

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.69

Market Cap

934.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBXG
EVO
Founded
N/A
1993
Country
United States
Germany
Employees
N/A
4553
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
934.1M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NBXG
EVO
Price
$15.42
$2.69
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
156.4K
94.1K
Earning Date
01-01-0001
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.37
Revenue Next Year
N/A
$10.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.32
$2.31
52 Week High
$15.87
$4.80

Technical Indicators

Market Signals
Indicator
NBXG
EVO
Relative Strength Index (RSI) 65.90 36.25
Support Level $14.50 $2.32
Resistance Level $15.54 $3.78
Average True Range (ATR) 0.24 0.09
MACD 0.03 -0.06
Stochastic Oscillator 75.90 6.44

Price Performance

Historical Comparison
NBXG
EVO

About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.

Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in NextGen Companies.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: